Answers are grounded in this paper and cite their sources.
The results of our study show that CD diagnosis still relies on intestinal biopsy in the Mediterranean area. New ESPGHAN criteria are not applicable in 5 countries due to lack of resources needed to perform HLA genotyping and, in one country, EMA assay. Further simplification of the new ESPGHAN guidelines might be made according to what preliminarily the present results suggest if confirmed by new prospective studies.
No takes yet. Share an insight, caveat, or question.
Smarrazzo et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: